Brain Advance Access originally published online on May 5, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 127, No. 7, 1606-1615,
July 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh175
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy
Departments of 1 Neurology, 2 Epidemiology and 3 Neuroscience and Pathology, The Johns Hopkins University, Baltimore, MD and 4 Georgetown University, Washington, USA
Correspondence to: Dr Michael Polydefkis, The Johns Hopkins Hospital, 600 North Wolfe Street, Pathology 509, Baltimore, MD 21287, USA E-mail: mpolyde{at}jhmi.edu
We sought to develop and validate a standardized cutaneous nerve regeneration model and to define the rate of epidermal nerve fibre (ENF) regeneration first in healthy control subjects and then in neuropathic and neuropathy-free subjects with diabetes. Next, we assessed the effect of different factors on the rate of nerve fibre regeneration and investigated whether such an approach might offer insight into novel trial designs and outcome measures. All subjects had a standardized topical capsaicin dressing applied to the distal lateral thigh. ENF densities derived from skin biopsies were determined at baseline, after capsaicin treatment and at reinnervation time points. For each subject, the best fit line from post-denervation data was determined and the slope was used as the rate of regeneration. In healthy control subjects, regeneration was correlated with psychophysical sensory testing, electron microscopy studies and immunohistochemistry with alternative axonal membrane markers. Topical capsaicin application produced complete or nearly complete denervation of the epidermis in both control subjects and people with diabetes. The rate of regeneration was associated with the baseline ENF density (P < 0.001), but not age (P = 0.75), gender (P = 0.18), epidermal thickness (P = 0.4) or post-capsaicin treatment density (P = 0.7). ENF regeneration, as determined by recovery of ENF density, occurred at a rate of 0.177 ± 0.075 fibres/mm/day in healthy control subjects and was significantly reduced in subjects with diabetes (0.074 ± 0.064, P < 0.001) after adjusting for changes in baseline ENF density. Among subjects with diabetes, the presence of neuropathy was associated with a further reduction in regenerative rate (0.10 ± 0.07 versus 0.04 ± 0.03, P = 0.03), though diabetes type (P = 0.7), duration of diabetes (P = 0.3) or baseline glycated haemoglobin (P = 0.6) were not significant. These results have several implications. First, topical capsaicin application can produce a uniform epidermal nerve fibre injury that is safe and well tolerated, and offers an efficient strategy to measure and study nerve regeneration in man. Secondly, using our techniques, reduced rates of nerve regeneration were found in people with diabetes without evidence of neuropathy and indicate that abnormalities in peripheral nerve function are present early in diabetes, before signs or symptoms develop. These results suggest that regenerative neuropathy trials could include non-neuropathic subjects and that trial duration can be dramatically shortened.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Duran-Jimenez, D. Dobler, S. Moffatt, N. Rabbani, C. H. Streuli, P. J. Thornalley, D. R. Tomlinson, and N. J. Gardiner Advanced Glycation End Products in Extracellular Matrix Proteins Contribute to the Failure of Sensory Nerve Regeneration in Diabetes Diabetes, December 1, 2009; 58(12): 2893 - 2903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zherebitskaya, E. Akude, D. R. Smith, and P. Fernyhough Development of Selective Axonopathy in Adult Sensory Neurons Isolated From Diabetic Rats: Role of Glucose-Induced Oxidative Stress Diabetes, June 1, 2009; 58(6): 1356 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Gibbons, B. M. W. Illigens, N. Wang, and R. Freeman Quantification of sweat gland innervation: A clinical-pathologic correlation Neurology, April 28, 2009; 72(17): 1479 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T.M. Krishnan, C. Quattrini, M. Jeziorska, R. A. Malik, and G. Rayman Abnormal LDIflare but Normal Quantitative Sensory Testing and Dermal Nerve Fiber Density in Patients with Painful Diabetic Neuropathy Diabetes Care, March 1, 2009; 32(3): 451 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Quattrini, M. Jeziorska, A. J.M. Boulton, and R. A. Malik Reduced Vascular Endothelial Growth Factor Expression and Intra-Epidermal Nerve Fiber Loss in Human Diabetic Neuropathy Diabetes Care, January 1, 2008; 31(1): 140 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Quattrini, M. Tavakoli, M. Jeziorska, P. Kallinikos, S. Tesfaye, J. Finnigan, A. Marshall, A. J.M. Boulton, N. Efron, and R. A. Malik Surrogate Markers of Small Fiber Damage in Human Diabetic Neuropathy Diabetes, August 1, 2007; 56(8): 2148 - 2154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Johanek, R. A. Meyer, T. Hartke, J. G. Hobelmann, D. N. Maine, R. H. LaMotte, and M. Ringkamp Psychophysical and Physiological Evidence for Parallel Afferent Pathways Mediating the Sensation of Itch J. Neurosci., July 11, 2007; 27(28): 7490 - 7497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lauria and R. Lombardi Skin biopsy: a new tool for diagnosing peripheral neuropathy BMJ, June 2, 2007; 334(7604): 1159 - 1162. [Full Text] [PDF]
|
|
|
|
|
|
D. N. Herrmann and M. B. Bromberg Chili peppers, nerve regeneration, and clinical trial design Neurology, April 17, 2007; 68(16): 1247 - 1248. [Full Text] [PDF]
|
|
|
|
|
|
K. Hahn, A. Triolo, P. Hauer, J. C. McArthur, and M. Polydefkis Impaired reinnervation in HIV infection following experimental denervation Neurology, April 17, 2007; 68(16): 1251 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Caterina Transient receptor potential ion channels as participants in thermosensation and thermoregulation Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R64 - R76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Orstavik, B. Namer, R. Schmidt, M. Schmelz, M. Hilliges, C. Weidner, R. W. Carr, H. Handwerker, E. Jorum, and H. E. Torebjork Abnormal Function of C-Fibers in Patients with Diabetic Neuropathy. J. Neurosci., November 1, 2006; 26(44): 11287 - 11294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Cheng, E. W. Gregg, H. S. Kahn, D. E. Williams, N. De Rekeneire, and K. M. V. Narayan Peripheral Insensate Neuropathy--A Tall Problem for US Adults? Am. J. Epidemiol., November 1, 2006; 164(9): 873 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bianchi, M. Brines, G. Lauria, C. Savino, A. Gilardini, G. Nicolini, V. Rodriguez-Menendez, N. Oggioni, A. Canta, P. Penza, et al. Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity Clin. Cancer Res., April 15, 2006; 12(8): 2607 - 2612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sorensen, L. Molyneaux, and D. K. Yue The Relationship Among Pain, Sensory Loss, and Small Nerve Fibers in Diabetes Diabetes Care, April 1, 2006; 29(4): 883 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Argoff, M.-M. Backonja, M. J. Belgrade, G. J. Bennett, M. R. Clark, B. E. Cole, D. A. Fishbain, G. A. Irving, B. H. McCarberg, and M. J. McLean Consensus Guidelines: Treatment Planning and Options Mayo Clin. Proc., April 1, 2006; 81(4_Suppl): S12 - S25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Polydefkis, M. Sirdofsky, P. Hauer, B. G. Petty, B. Murinson, and J. C. McArthur Factors influencing nerve regeneration in a trial of timcodar dimesylate Neurology, January 24, 2006; 66(2): 259 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Cherry, S. L. Wesselingh, L. Lal, and J. C. McArthur Evaluation of a clinical screening tool for HIV-associated sensory neuropathies Neurology, December 13, 2005; 65(11): 1778 - 1781. [Abstract] [Full Text] [PDF]
|
|